# US 2025/0375489 A1 · Combination Therapy for Treatment of Muscle Loss Due to Obesity Treatments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375489 A1
- Document ID: US20250375489A1
- Status: Published application
- Kind: A1
- Application number: 19/191,226
- Filed: 2025-04-28
- Published: 2025-12-11
- Earliest claimed: 2024-04-29
- Assignees: Northstrive Biosciences, Inc.
- Applicants: Northstrive Biosciences, Inc.
- Inventors: Jordan Robert Plews; Deniel Mero
- Web page: https://patentgrep.com/patent/US20250375489A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 38/164: {from bacteria}
- A61K 38/1719: {Muscle proteins, e.g. myosin or actin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 15/746: {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a combination therapy of an approved GLP-1 receptor agonist treatment and a microorganism transformed with a cell surface display vector operably linked with a gene encoding myostatin and activin A proteins for the treatment of muscle loss related to obesity. The microorganism may be formulated to include pharmaceutically viable excipients, such as antiadherents, binders, carriers, coatings, colorants, disintegrants, diluents, flavorings, glidants, lubricants, preservatives, sorbents, or vehicles.

## Claims

### Claim 1

A combination therapy, comprising an approved GLP-1 receptor agonist treatment and a microorganism transformed with a cell surface display vector operably linked to a gene encoding myostatin and activin A proteins, wherein the combination therapy is used for the treatment of muscle loss related to obesity treatments.

### Claim 2 (depends on 1)

The combination therapy of claim 1, wherein the cell surface display vector includes a pgsA gene.

### Claim 3 (depends on 1)

The combination therapy of claim 1, wherein the myostatin has a gene sequence of SEQ ID NO: 1.

### Claim 4 (depends on 1)

The combination therapy of claim 1, wherein the activin A has a gene sequence of SEQ ID NO: 2.

### Claim 5 (depends on 1)

The combination therapy of claim 1, wherein the microorganism is a lactic acid bacterium.

### Claim 6 (depends on 5)

The combination therapy of claim 5, where in the lactic acid bacterium is Lactobacillus paracasei.

### Claim 7 (depends on 1)

The combination therapy of claim 1, further comprising at least one pharmaceutically viable excipient combined with the microorganism.

### Claim 8 (depends on 7)

The combination therapy of claim 7, wherein the at least one pharmaceutically viable excipient is selected from the group consisting of antiadherents, binders, carriers, coatings, colorants, disintegrants, diluents, flavorings, glidants, lubricants, preservatives, sorbents, and vehicles.